Incontinentia pigmenti (IP, Bloch-Sulzberger syndrome) is an X-linked dominant genodermatosis affecting skin and other organs, including the brain, with variable expressivity. Incontinentia pigmenti results from mutations in the inhibitor of κ-β-kinase-γ gene (IKBKG), which is located on Xq28. Deletions in this gene result in loss of function, leading to a wide variety of manifestations.
Report of a Case | An infant girl, the product of consanguineous parents, presented at birth with erythematous vesicles on her hands, progressing to scaly, erythematous plaques on her head, neck, trunk, and extremities in a blaschkoid pattern. There were no neurological symptoms. Initial concern for infection led to several investigations. Results from blood culture and herpes simplex virus culture of a vesicle were negative. Cerebrospinal fluid showed elevated protein level of 0.063 g/dL (range, 0.015-0.06 g/dL; to convert to grams per liter, multiply by 10), glucose level of 52 mg/dL, and 0.004 nucleated cells/L, with negative herpes simplex virus polymerase chain reaction results. Aspartate aminotransferase level was elevated to 1355 U/L (range, 10-80 units/L; to convert to microkatals per liter, multiply by 0.0167), and the alanine aminotransferase level was elevated to 807 U/L (range, 10-50 U/L; to convert to microkatals per liter, multiply by 0.0167).
Fundoscopy revealed bilateral preretinal and retinal hemorrhages, extending to the maculae, as commonly seen in vaginally delivered infants. Brain magnetic resonance imaging showed multiple areas of restricted diffusion and intraparenchymal and leptomeningeal enhancement resembling hemophagocytic lymphohistiocytosis (Figure) . DNA sequencing for a panel of genes associated with hemophagocytic lymphohistiocytosis was negative. Skin histopathological examination revealed dense inflammatory infiltrate with a myriad of eosinophils, prominent spongiosis with intraepidermal vesicles containing eosinophils, and several necrotic keratinocytes, consistent with the inflammatory stage of IP. The child harbored a common known pathogenic deletion in IKBKG, also known as activator of NF-κ-β or NEMO.
This study was approved by the University of Texas Southwestern Medical Center institutional review board.
Discussion | Skin manifestations are commonly the first symptom and occur in nearly all patients with IP. They follow Blaschko lines. Our patient had inflammatory lesions (Figure) . Eye abnormalities include retinal anomalies, such as telangiectasia, hemorrhage, arteriovenous anastomoses, neovascularization, and retinal avascularity, or anomalies involving vitreous and lens, microphthalmia, and cataracts. Minor criteria include skin appendage abnormalities including the absence of pilosebaceous glands; alopecia; sparse, wooly hair; anomalies of eyebrows and eyelashes; nail pitting; dystrophy; and subungual or periungual tumors.
3 Nipple and dental anomalies may also be present. Neurological manifestations occur in the first month of life in two-thirds of cases with neurological involvement, which comprise as much as one-third of all IP cases. 4 They range from a single seizure to psychomotor delay, learning disabilities, hemiplegia, epilepsy, cerebellar ataxia, microcephaly, childhood encephalomyelitis, and strokelike episodes. Magnetic resonance imaging may reveal white matter and corpus callosum abnormalities, cortical malformations, cerebral atrophy, and cerebral or cerebellar hemorrhage. 5, 6 Although strokelike lesions secondary to focal cortical and white matter necrosis in a nonvascular distribution have been reported in IP, ring enhancement is unusual. Our patient manifested ring enhancement in areas of restricted diffusion together with subtle, diffuse intraparenchymal, cerebellar, and leptomeningeal enhancement.
Conclusions | The rarity of IP together with its myriad clinical presentations poses a significant diagnostic challenge. The presentation of IP may mimic other blaschkoid pigmentary disorders such as hypomelanosis of Ito, focal dermal hypoplasia (Goltz syndrome), or herpes simplex virus infection. The neurological syndrome of IP is even less specific. In the absence of cerebral Citrobacter or fungal infection, the diffuse radially distributed ring-enhancement appearance of our case by magnetic resonance imaging is most suggestive of cellular loss along migrational trajectories.
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COMMENT & RESPONSE Treating In-Hospital Stroke
To the Editor Saltman et al 1 found delays in the evaluation and treatment of patients who had a stroke while hospitalized for another condition compared with those whose strokes occurred in the community. A "standardized approach to the recognition and management of in-hospital stroke" by developing "targeted code stroke protocols…similar to those used in the emergency department" was suggested. 1 We previously reported the usefulness of such a protocol for hospitalized patients, comparing the yield of "stroke codes" between the in-hospital and emergency department (ED) settings in a single institution. 2 We found that hospitalized patients for whom a stroke code was activated were less likely to have a stroke/transient ischemic attack (26.8% in-hospital vs 51.4% ED; P < .001) and less likely to be treated with intravenous tissue plasminogen activator (odds ratio, 0.27; 95% CI, 0.07-0.97; P = .03). Conditions not necessitating immediate neurologic care accounted for 63.4% of in-hospital stroke codes compared with 31.3% of those arising in the ED (P < .001). Altered mental status was the sole presenting symptom in 48% of the hospitalized patients compared with only 10% of ED patients (P < .001) and was independently associated with a stroke mimic (odds ratio, 63.52; 95% CI, 7.37-547.69; P < .001). There was no association between the diagnosis of an in-hospital stroke mimic and patient age, sex, race/ ethnicity, or nursing shift. Similar to the study by Saltman et al, 1 we found that the proportion of hospitalized patients with acute ischemic stroke who were treated with intravenous tissue plasminogen activator after activation of an in-hospital code stroke was small, and it was lower than for those who presented to the ED (2.7% vs 25.9%, respectively; P = .004). We suggested that although a standardized stroke code protocol may be an initial step for improving treatment rates among hospitalized patients, it is not likely to entirely eliminate the differences as compared with patients evaluated in the ED because of the high proportions of stroke mimics and treatment contraindications in hospitalized patients. In addition to having a standardized in-hospital stroke code protocol, training all hospital personnel in accurate stroke recognition will help improve the identification of those patients appropriate for intravenous tissue plasminogen activator or endovascular therapy and optimize resource use.
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